932372-87-7

Usage

Molecular weight

298.4 g/mol

Chemical class

Sulfonyl piperazine derivative

Application

Medicinal chemistry and drug development

Pharmacological properties

Inhibition of certain enzymes and receptors in the body

Potential therapeutic interventions

Various disease conditions

Mechanism of action

Under investigation

Therapeutic applications

Under investigation
Please note that this list is based on the provided material and may not be exhaustive. Further research and investigation are required to fully understand the properties and potential applications of 1-[[4-(1-methylethoxy)phenyl]sulfonyl]Piperazine.

Upstream product

• 98995-40-5 4-isopropoxybenzene-1-sulfonyl chloride 

Downstream Products

• 932372-96-8 C₁₉H₂₃N₃O₆S 
• 932373-09-6 C₂₉H₃₁N₃O₅S 
• 932373-13-2 C₂₉H₃₁N₃O₅S 
• 932373-10-9 5-[4-(4-isopropyloxyphenylsulfonyl)piperazine-1-yl]-2-(1,3-oxazole-2-yl)phenol 
• 932372-01-5 [2-(oxazol-2-yl)-5-(4-{4-[(propan-2-yl)oxy]phenylsulfonyl}piperazine-1-yl)phenoxy]acetic acid 

Relevant academic research and scientific papers

SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY

The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A comp

SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY

A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represented by the general formula (II): (II) (wherein ring A is an aromatic carbocycle, etc.; ring B is a nitrogenous nonaromatic heterocycle, etc.; ring C is an aromatic carbocycle, etc.; R1 is carboxy, etc.; R2's each independently is halogeno, etc.; R3 is optionally substituted alkyloxy, etc.; R4's each independently is halogeno, etc.; R5's each independently is optionally substituted alkyl, etc.; M is sulfonyl, etc.; Y is a single bond, etc.; L1 is a single bond, etc.; L2 is a single bond, etc.; k is 0, 1, 2, 3, or 4; n is 0, 1, or 2; and q is 0, 1, 2, or 3, provided that, for example, a) when ring B is a 6-membered nitrogenous heterocycle containing one or two nitrogen atoms and ring C is a benzene ring, then k is not 0), a pharmaceutically acceptable salt of the compound, or a hydrate of either.